11 research outputs found
Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors
Checkpoint inhibitors have improved the survival of patients with advanced tumors and show
a manageable toxicity profile. However, auto-immune colitis remains a relevant side effect, and combinations of anti-PD1/PDL1 and anti-CTLA-4 increase its incidence and severity. Here, we report the case of
a 50-year-old patient diagnosed with stage IV cervical cancer that relapsed following radical surgery,
external radiation/brachytherapy and standard chemotherapy. She was subsequently treated with
Nivolumab and Ipilimumab combination and developed grade 2 colitis presenting a dissociation
between endoscopic and pathological findings. At cycle 10 the patient reported grade 3 diarrhea and
abdominal discomfort, without blood or mucus in the stools. Immunotherapy was withheld and
a colonoscopy was performed, showing normal mucosa in the entire colon. Puzzlingly, histologic
evaluation of randomly sampled mucosal biopsy of the distal colon showed an intense intraepithelial
lymphocyte infiltration with crypt loss and some regenerating crypts with a few apoptotic bodies set in
a chronically inflamed lamina propria, consistent with the microscopic diagnosis of colitis. Treatment
with methylprednisolone 2 mg/kg was initiated which led to a decrease in the number of stools to grade
1. Additional investigations to exclude other causes of diarrhea rendered negative results. The patient
experienced a major partial response and, following the resolution of diarrhea, she was re-challenged
again with immunotherapy, with the reappearance of grade 2 diarrhea, leading to permanent immunotherapy interruption. We conclude and propose that performing random colonic biopsies should be
considered in cases of immune checkpoint-associated unexplained diarrhea, even when colonoscopy
shows macroscopically normal colonic mucosa inflammatory lesions
Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8
Neutrophil extracellular traps (NETs) are webs of extracellular nuclear DNA extruded by dying neutrophils infiltrating
tissue. NETs constitute a defence mechanism to entrap and kill fungi and bacteria. Tumours induce the formation of
NETs to the advantage of the malignancy via a variety of mechanisms shown in mouse models. Here, we investigated
the presence of NETs in a variety of human solid tumours and their association with IL-8 (CXCL8) protein expression
and CD8+ T-cell density in the tumour microenvironment. Multiplex immunofluorescence panels were developed to
identify NETs in human cancer tissues by co-staining with the granulocyte marker CD15, the neutrophil marker myeloperoxidase
and citrullinated histone H3 (H3Cit), as well as IL-8 protein and CD8+ T cells. Three ELISA methods to
detect and quantify circulating NETs in serum were optimised and utilised. Whole tumour sections and tissue microarrays
from patients with non-small cell lung cancer (NSCLC; n = 14), bladder cancer (n = 14), melanoma (n = 11),
breast cancer (n = 31), colorectal cancer (n = 20) and mesothelioma (n = 61) were studied. Also, serum samples
collected retrospectively from patients with metastatic melanoma (n = 12) and NSCLC (n = 34) were ELISA assayed
to quantify circulating NETs and IL-8. NETs were detected in six different human cancer types with wide individual
variation in terms of tissue density and distribution. At least in NSCLC, bladder cancer and metastatic melanoma, NET
density positively correlated with IL-8 protein expression and inversely correlated with CD8+ T-cell densities. In a
series of serum samples from melanoma and NSCLC patients, a positive correlation between circulating NETs and
IL-8 was found. In conclusion, NETs are detectable in formalin-fixed human biopsy samples from solid tumours
and in the circulation of cancer patients with a considerable degree of individual variation. NETs show a positive
association with IL-8 and a trend towards a negative association with CD8+ tumour-infiltrating lymphocytes
Differentiation stage of myeloma plasma cells: biological and clinical significance
[EN] The notion that plasma cells (PCs) are terminally differentiated has prevented intensive research in multiple myeloma (MM) about their phenotypic plasticity and differentiation. Here, we demonstrated in healthy individuals (n = 20) that the CD19 − CD81 expression axis identifies three bone marrow (BM)PC subsets with distinct age-prevalence, proliferation, replication-history, immunoglobulin-production, and phenotype, consistent with progressively increased differentiation from CD19+CD81+ into CD19 − CD81+ and CD19 − CD81 − BMPCs. Afterwards, we demonstrated in 225 newly diagnosed MM patients that, comparing to normal BMPC counterparts, 59% had fully differentiated (CD19 − CD81 −) clones, 38% intermediate-differentiated (CD19 − CD81+) and 3% less-differentiated (CD19+CD81+) clones. The latter patients had dismal outcome, and PC differentiation emerged as an independent prognostic marker for progression-free (HR: 1.7; P = 0.005) and overall survival (HR: 2.1; P = 0.006). Longitudinal comparison of diagnostic vs minimal-residual-disease samples (n = 40) unraveled that in 20% of patients, less-differentiated PCs subclones become enriched after therapy-induced pressure. We also revealed that CD81 expression is epigenetically regulated, that less-differentiated clonal PCs retain high expression of genes related to preceding B-cell stages (for example: PAX5), and show distinct mutation profile vs fully differentiated PC clones within individual patients. Together, we shed new light into PC plasticity and demonstrated that MM patients harbouring less-differentiated PCs have dismal survival, which might be related to higher chemoresistant potential plus different molecular and genomic profiles
Challenges of ICC and FISH in the Field of Targeted Therapies from Cell Block to Smears
In the era of personalized medicine, there is an increasing demand for comprehensive and complex diagnosis using minimally invasive techniques. Nowadays, it is mandatory to integrate biomarkers in the diagnostic process, as well as in the treatment and clinical management of many cancer patients. Patients with non-small cell lung cancer (NSCLC), for instance, are frequently diagnosed in advanced stages, at a point when only cytological material or small biopsies can be obtained. This pathology constitutes an interesting challenge for the testing of biomarkers in cytology. Furthermore, there is a growing development of imaging techniques that guide non-invasive approaches to obtain small biopsies or cytological samples. This has allowed fine needle aspiration cytology and fine needle aspiration biopsy (FNAC, FNAB) to become front-line procedures in the management of patients with NSCLC. It is well known that the list of biomarkers to be tested in these patients continues to increase. Nevertheless, there are several of essential biomarkers that should always be analyzed in all patients with NSCLC, not only in non-squamous but also in some squamous carcinomas (SqCC). Some of them, such as PDL1, are tested by immunocytochemistry (ICC), while others, mainly ALK and ROS1, can be tested by ICC and confirmed using other techniques such a Fluorescence In Situ Hybridization (FISH). Other biomarkers, namely EGFR and BRAF mutations, are currently evaluated by polymerase chain reaction (PCR)-based techniques including Next-Generation Sequencing (NGS). In this review, we will address the particularities and challenges that ICC and FISH pose in different types of cytological samples from an eminently practical point of view
Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors
Checkpoint inhibitors have improved the survival of patients with advanced tumors and show a manageable toxicity profile. However, auto-immune colitis remains a relevant side effect, and combinations of anti-PD1/PDL1 and anti-CTLA-4 increase its incidence and severity. Here, we report the case of a 50-year-old patient diagnosed with stage IV cervical cancer that relapsed following radical surgery, external radiation/brachytherapy and standard chemotherapy. She was subsequently treated with Nivolumab and Ipilimumab combination and developed grade 2 colitis presenting a dissociation between endoscopic and pathological findings. At cycle 10 the patient reported grade 3 diarrhea and abdominal discomfort, without blood or mucus in the stools. Immunotherapy was withheld and a colonoscopy was performed, showing normal mucosa in the entire colon. Puzzlingly, histologic evaluation of randomly sampled mucosal biopsy of the distal colon showed an intense intraepithelial lymphocyte infiltration with crypt loss and some regenerating crypts with a few apoptotic bodies set in a chronically inflamed lamina propria, consistent with the microscopic diagnosis of colitis. Treatment with methylprednisolone 2 mg/kg was initiated which led to a decrease in the number of stools to grade 1. Additional investigations to exclude other causes of diarrhea rendered negative results. The patient experienced a major partial response and, following the resolution of diarrhea, she was re-challenged again with immunotherapy, with the reappearance of grade 2 diarrhea, leading to permanent immunotherapy interruption. We conclude and propose that performing random colonic biopsies should be considered in cases of immune checkpoint-associated unexplained diarrhea, even when colonoscopy shows macroscopically normal colonic mucosa inflammatory lesions
Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis
Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis
OBJECTIVES: Liver metastases appear in 20–30% of patients diagnosed with non-small cell lung cancer (NSCLC) and represent a poor prognosis feature of NSCLC and a possibly more treatment-resistant condition. Potential clinical outcome differences in NSCLC patients with liver metastases harboring molecular alterations in EGFR, KRAS and EML4-ALK genes are still to be determined. This study aims to evaluate the incidence of liver metastasis in a single population and look for potential correlations between EGFR mutations, liver infiltration and clinical outcomes. METHODS: A total of 236 consecutive stage IV NSCLC patients treated at the Clínica Universidad de Navarra were analyzed. RESULTS: At onset, liver metastases were present in 16.9% of patients conferring them a shorter overall survival (OS) compared to those with different metastatic locations excluding liver infiltration (10 vs. 21 months; p = 0.001). Patients with EGFR wild-type tumors receiving standard chemotherapy and showing no liver involvement presented a superior median OS compared to those with liver metastases (23 vs. 13 months; p = 0.001). Conversely, patients with EGFR-mutated tumors treated with EGFR tyrosin-kinase inhibitors (TKI’s) presented no significant differences in OS regardless of liver involvement (median OS not reached vs. 25 months; p = 0.81). CONCLUSION: Overall, liver metastases at onset negatively impact OS of NSCLC patients. EGFR TKIs however, may reverse the effects of an initial negative prognosis of liver metastasis in first-line treatment of EGFR mutated NSCLC patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0622-x) contains supplementary material, which is available to authorized users
Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes
EGFR and K-ras mutation status was determined from tumor DNA extracted from cytological samples from non-small cell lung cancer patients, with results comparable with those from biopsy samples. Clinical outcomes of patients harboring mutations and their response to tyrosine kinase inhibitor therapy are also discussed
Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors
Checkpoint inhibitors have improved the survival of patients with advanced tumors and show
a manageable toxicity profile. However, auto-immune colitis remains a relevant side effect, and combinations of anti-PD1/PDL1 and anti-CTLA-4 increase its incidence and severity. Here, we report the case of
a 50-year-old patient diagnosed with stage IV cervical cancer that relapsed following radical surgery,
external radiation/brachytherapy and standard chemotherapy. She was subsequently treated with
Nivolumab and Ipilimumab combination and developed grade 2 colitis presenting a dissociation
between endoscopic and pathological findings. At cycle 10 the patient reported grade 3 diarrhea and
abdominal discomfort, without blood or mucus in the stools. Immunotherapy was withheld and
a colonoscopy was performed, showing normal mucosa in the entire colon. Puzzlingly, histologic
evaluation of randomly sampled mucosal biopsy of the distal colon showed an intense intraepithelial
lymphocyte infiltration with crypt loss and some regenerating crypts with a few apoptotic bodies set in
a chronically inflamed lamina propria, consistent with the microscopic diagnosis of colitis. Treatment
with methylprednisolone 2 mg/kg was initiated which led to a decrease in the number of stools to grade
1. Additional investigations to exclude other causes of diarrhea rendered negative results. The patient
experienced a major partial response and, following the resolution of diarrhea, she was re-challenged
again with immunotherapy, with the reappearance of grade 2 diarrhea, leading to permanent immunotherapy interruption. We conclude and propose that performing random colonic biopsies should be
considered in cases of immune checkpoint-associated unexplained diarrhea, even when colonoscopy
shows macroscopically normal colonic mucosa inflammatory lesions
Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients
BRAF V600 mutation has been reported in more than 50% of melanoma cases and its presence predicts clinical
activity of BRAF inhibitors (iBRAF). We evaluated the role of MIA, S100 and LDH to monitor iBRAF efficiency in
advanced melanoma patients presenting BRAF V600 mutations. This was a prospective study of melanoma
patients harboring the BRAF V600 mutation and treated with iBRAF within a clinical trial (dabrafenib) or as
part of an expanded access program (vemurafenib). MIA, S100 and LDH were analyzed in serum at baseline,
and every 4–6 weeks during treatment. Eighteen patients with melanoma stages IIIc–IV were enrolled with
88.8% of response rate to iBRAF. Baseline concentrations of all the tumor markers correlated with tumor burden.
MIA and S100 concentrations decreased significantly one month after the beginning of treatment and, upon progression, their concentrations increased significantly above the minimum levels previously achieved. MIA levels
lower than 9 μg/L one month after the beginning of treatment and S100 concentrations lower than 0.1 μg/L at the
moment of best response were associated with improved progression-free survival. In conclusion, MIA and S100
are useful to monitor response in melanoma patients treated with iBRA